Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral prophylaxis Clear all
Completed Phase 2 Interventional

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

NCT00066599
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Sirolimus in Preventing Functional Decline in Older Adults

NCT05237687
View directory record Official record
Conditions
Aging
Interventions
Sirolimus
Drug
Lead sponsor
Irina Timofte
Other
Eligibility
65 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Phase 2 Interventional

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

NCT01451853
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
Interventions
SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 1 Interventional

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

NCT00000739
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Not applicable Interventional

Barotrauma in Hyperbaric Oxygen Therapy

NCT05697328
View directory record Official record
Conditions
Barotrauma
Interventions
Pseudoephedrine Pill, Placebo
Drug
Lead sponsor
John Muir Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Phase 3 Interventional

Macitentan to Prevent PRVO

NCT05946811
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Macitentan 10mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Phase 4 Interventional

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

NCT06866691
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
levetiracetam, lacosamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

NCT03278808
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 23, 2026, 8:53 PM EDT
Not listed Phase 3 Interventional

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

NCT04935476
View directory record Official record
Conditions
COVID-19
Interventions
Dapsone 85 mg PO BID, Placebo 85 mg PO BID
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
40 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Osteoporosis

NCT00421343
View directory record Official record
Conditions
Osteoporosis
Interventions
alendronate with cholecalciferol, calcium carbonate with cholecalciferol, Falls prevention measures
Drug · Behavioral
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 23, 2026, 8:53 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Advancing Postmenopausal Preventive Therapy

NCT04103476
View directory record Official record
Conditions
Atherosclerosis, Cognitive Decline
Interventions
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo
Combination Product · Other
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

NCT00501059
View directory record Official record
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

NCT02830932
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose)
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 1 Interventional

Cyclosporine in Patients With Moderate COVID-19

NCT04412785
View directory record Official record
Conditions
COVID-19
Interventions
Cyclosporine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 23, 2026, 8:53 PM EDT
Not yet recruiting Phase 1 Interventional

Psilocybin After Trauma Surgery for Pain

NCT07406828
View directory record Official record
Conditions
Pain Management, Postoperative Pain
Interventions
Psilocybin (Usona Institute), Postoperative analgesia
Drug
Lead sponsor
Trent Emerick
Other
Eligibility
25 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Not applicable Interventional

Breathing Rescue for SUDEP Prevention

NCT05981755
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Breathing tasks, Brain mapping with stimulation
Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

NCT04007367
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
46
States / cities
Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 23, 2026, 8:53 PM EDT
Active, not recruiting Phase 3 Interventional

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

NCT03978000
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
IBP-9414, Placebo
Drug
Lead sponsor
Infant Bacterial Therapeutics
Industry
Eligibility
Up to 48 Hours
Enrollment
2,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 23, 2026, 8:53 PM EDT